AG˹ٷ

STOCK TITAN

[8-K] abrdn Income Credit Strategies Fund Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Teva Pharmaceutical Industries Ltd. (TEVA) has filed a Form 144 announcing the possible sale of 52,742 ordinary shares through Citigroup Global Markets on or about 01-Aug-2025. The shares carry an estimated aggregate market value of $799,437 and equal roughly 0.005 % of the 1.15 billion shares outstanding, indicating a very small portion of the company’s float. The seller—an unnamed insider—received the stock on 01-Aug-2022 via a restricted share-unit (RSU) award. No other sales have been reported in the past three months. A Form 144 is a notice, not a guarantee, but signals that the insider may execute the transaction on the NYSE under Rule 144. Given the modest size and compensation-related origin, market impact is expected to be minimal, though insider sales can be perceived as a slight negative sentiment indicator.

Teva Pharmaceutical Industries Ltd. (TEVA) ha presentato un Modulo 144 annunciando la possibile vendita di 52.742 azioni ordinarie tramite Citigroup Global Markets intorno al 01-ago-2025. Le azioni hanno un valore di mercato aggregato stimato di 799.437 $ e rappresentano circa lo 0,005% delle 1,15 miliardi di azioni in circolazione, indicando una quota molto piccola del flottante della società. Il venditore � un insider non identificato � ha ricevuto le azioni il 01-ago-2022 tramite un premio in azioni vincolate (RSU). Non sono state segnalate altre vendite negli ultimi tre mesi. Il Modulo 144 è un avviso, non una garanzia, ma indica che l’insider potrebbe eseguire la transazione sul NYSE secondo la Regola 144. Data la dimensione modesta e l’origine legata a compensi, l’impatto sul mercato dovrebbe essere minimo, anche se le vendite da parte di insider possono essere percepite come un leggero indicatore di sentiment negativo.

Teva Pharmaceutical Industries Ltd. (TEVA) ha presentado un Formulario 144 anunciando la posible venta de 52.742 acciones ordinarias a través de Citigroup Global Markets alrededor del 01-ago-2025. Las acciones tienen un valor de mercado agregado estimado de 799.437 $ y representan aproximadamente el 0,005 % de las 1,15 mil millones de acciones en circulación, indicando una porción muy pequeña del flotante de la empresa. El vendedor, un insider no identificado, recibió las acciones el 01-ago-2022 mediante una concesión de unidades restringidas de acciones (RSU). No se han reportado otras ventas en los últimos tres meses. Un Formulario 144 es un aviso, no una garantía, pero señala que el insider podría ejecutar la transacción en la NYSE bajo la Regla 144. Dado el tamaño modesto y el origen relacionado con compensación, se espera que el impacto en el mercado sea mínimo, aunque las ventas de insiders pueden percibirse como un ligero indicador de sentimiento negativo.

Teva Pharmaceutical Industries Ltd. (TEVA)2025� 8� 1일경 Citigroup Global Markets� 통해 52,742� 보통�� 매도� 가능성� 알리� Form 144� 제출했습니다. 해당 주식� 추정 � 시장 가치 799,437달러이며, 발행 주식 11� 5천만 주의 � 0.005%� 해당하여 회사 유통 주식� 매우 작은 부분임� 나타냅니�. 판매자 이름� 공개되지 않은 내부자이�, 2022� 8� 1� 제한 주식 단위(RSU) 보상� 통해 주식� 받았습니�. 지� 3개월 동안 다른 매도 보고� 없었습니�. Form 144� 통지서일 � 보장하 것은 아니지�, 내부자가 NYSE에서 규칙 144� 따라 거래� 실행� � 있음� 시사합니�. 규모가 작고 보상 관� 주식임을 고려� � 시장� 미치� 영향은 미미� 것으� 예상되지�, 내부� 매도� 약간� 부정적 심리 신호� 해석� � 있습니다.

Teva Pharmaceutical Industries Ltd. (TEVA) a déposé un formulaire 144 annonçant la possible vente de 52 742 actions ordinaires via Citigroup Global Markets aux alentours du 01-û-2025. Les actions ont une valeur marchande agrégée estimée à 799 437 $ et représentent environ 0,005 % des 1,15 milliard d’actions en circulation, indiquant une part très faible du flottant de la société. Le vendeur � un initié non nommé � a reçu ces actions le 01-û-2022 dans le cadre d’une attribution de restricted share units (RSU). Aucune autre vente n’a été rapportée au cours des trois derniers mois. Un formulaire 144 est un avis, non une garantie, mais indique que l’initié pourrait effectuer la transaction sur le NYSE selon la règle 144. Étant donné la taille modeste et l’origine liée à une rémunération, l’impact sur le marché devrait être minimal, bien que les ventes d’initiés puissent être perçues comme un léger indicateur de sentiment négatif.

Teva Pharmaceutical Industries Ltd. (TEVA) hat ein Formular 144 eingereicht, in dem der mögliche Verkauf von 52.742 Stammaktien über Citigroup Global Markets um den 01.08.2025 angekündigt wird. Die Aktien haben einen geschätzten Gesamtmarktwert von 799.437 $ und entsprechen etwa 0,005 % der 1,15 Milliarden ausstehenden Aktien, was einen sehr kleinen Teil des Streubesitzes des Unternehmens darstellt. Der Verkäufer � ein nicht namentlich genannter Insider � erhielt die Aktien am 01.08.2022 durch eine Restricted Share-Unit (RSU)-Zuteilung. In den letzten drei Monaten wurden keine weiteren Verkäufe gemeldet. Ein Formular 144 ist eine Mitteilung, keine Garantie, signalisiert jedoch, dass der Insider die Transaktion an der NYSE gemäß Regel 144 ausführen könnte. Aufgrund der geringen Größe und des vergütungsbezogenen Ursprungs wird erwartet, dass die Marktauswirkungen minimal sind, obwohl Insiderverkäufe als leicht negatives Stimmungsindikator wahrgenommen werden können.

Positive
  • None.
Negative
  • Insider plans to sell 52,742 shares worth approximately $0.8 M, which can be viewed as a slight negative sentiment signal.

Insights

TL;DR: Very small insider sale (~$0.8 M, 0.005 % float); signal mildly negative but fundamentally immaterial.

The filing reveals an insider’s intent to sell 52,742 RSU-derived shares. With 1.15 Bn shares outstanding, the sale is de minimis, unlikely to influence liquidity or price dynamics. Because the stock was earned via compensation and the insider has made no recent sales, the move could reflect routine diversification rather than concern over fundamentals. Investors may note it as a marginally bearish sentiment cue, yet the absence of additional negative disclosures or large volume keeps the overall impact neutral.

Teva Pharmaceutical Industries Ltd. (TEVA) ha presentato un Modulo 144 annunciando la possibile vendita di 52.742 azioni ordinarie tramite Citigroup Global Markets intorno al 01-ago-2025. Le azioni hanno un valore di mercato aggregato stimato di 799.437 $ e rappresentano circa lo 0,005% delle 1,15 miliardi di azioni in circolazione, indicando una quota molto piccola del flottante della società. Il venditore � un insider non identificato � ha ricevuto le azioni il 01-ago-2022 tramite un premio in azioni vincolate (RSU). Non sono state segnalate altre vendite negli ultimi tre mesi. Il Modulo 144 è un avviso, non una garanzia, ma indica che l’insider potrebbe eseguire la transazione sul NYSE secondo la Regola 144. Data la dimensione modesta e l’origine legata a compensi, l’impatto sul mercato dovrebbe essere minimo, anche se le vendite da parte di insider possono essere percepite come un leggero indicatore di sentiment negativo.

Teva Pharmaceutical Industries Ltd. (TEVA) ha presentado un Formulario 144 anunciando la posible venta de 52.742 acciones ordinarias a través de Citigroup Global Markets alrededor del 01-ago-2025. Las acciones tienen un valor de mercado agregado estimado de 799.437 $ y representan aproximadamente el 0,005 % de las 1,15 mil millones de acciones en circulación, indicando una porción muy pequeña del flotante de la empresa. El vendedor, un insider no identificado, recibió las acciones el 01-ago-2022 mediante una concesión de unidades restringidas de acciones (RSU). No se han reportado otras ventas en los últimos tres meses. Un Formulario 144 es un aviso, no una garantía, pero señala que el insider podría ejecutar la transacción en la NYSE bajo la Regla 144. Dado el tamaño modesto y el origen relacionado con compensación, se espera que el impacto en el mercado sea mínimo, aunque las ventas de insiders pueden percibirse como un ligero indicador de sentimiento negativo.

Teva Pharmaceutical Industries Ltd. (TEVA)2025� 8� 1일경 Citigroup Global Markets� 통해 52,742� 보통�� 매도� 가능성� 알리� Form 144� 제출했습니다. 해당 주식� 추정 � 시장 가치 799,437달러이며, 발행 주식 11� 5천만 주의 � 0.005%� 해당하여 회사 유통 주식� 매우 작은 부분임� 나타냅니�. 판매자 이름� 공개되지 않은 내부자이�, 2022� 8� 1� 제한 주식 단위(RSU) 보상� 통해 주식� 받았습니�. 지� 3개월 동안 다른 매도 보고� 없었습니�. Form 144� 통지서일 � 보장하 것은 아니지�, 내부자가 NYSE에서 규칙 144� 따라 거래� 실행� � 있음� 시사합니�. 규모가 작고 보상 관� 주식임을 고려� � 시장� 미치� 영향은 미미� 것으� 예상되지�, 내부� 매도� 약간� 부정적 심리 신호� 해석� � 있습니다.

Teva Pharmaceutical Industries Ltd. (TEVA) a déposé un formulaire 144 annonçant la possible vente de 52 742 actions ordinaires via Citigroup Global Markets aux alentours du 01-û-2025. Les actions ont une valeur marchande agrégée estimée à 799 437 $ et représentent environ 0,005 % des 1,15 milliard d’actions en circulation, indiquant une part très faible du flottant de la société. Le vendeur � un initié non nommé � a reçu ces actions le 01-û-2022 dans le cadre d’une attribution de restricted share units (RSU). Aucune autre vente n’a été rapportée au cours des trois derniers mois. Un formulaire 144 est un avis, non une garantie, mais indique que l’initié pourrait effectuer la transaction sur le NYSE selon la règle 144. Étant donné la taille modeste et l’origine liée à une rémunération, l’impact sur le marché devrait être minimal, bien que les ventes d’initiés puissent être perçues comme un léger indicateur de sentiment négatif.

Teva Pharmaceutical Industries Ltd. (TEVA) hat ein Formular 144 eingereicht, in dem der mögliche Verkauf von 52.742 Stammaktien über Citigroup Global Markets um den 01.08.2025 angekündigt wird. Die Aktien haben einen geschätzten Gesamtmarktwert von 799.437 $ und entsprechen etwa 0,005 % der 1,15 Milliarden ausstehenden Aktien, was einen sehr kleinen Teil des Streubesitzes des Unternehmens darstellt. Der Verkäufer � ein nicht namentlich genannter Insider � erhielt die Aktien am 01.08.2022 durch eine Restricted Share-Unit (RSU)-Zuteilung. In den letzten drei Monaten wurden keine weiteren Verkäufe gemeldet. Ein Formular 144 ist eine Mitteilung, keine Garantie, signalisiert jedoch, dass der Insider die Transaktion an der NYSE gemäß Regel 144 ausführen könnte. Aufgrund der geringen Größe und des vergütungsbezogenen Ursprungs wird erwartet, dass die Marktauswirkungen minimal sind, obwohl Insiderverkäufe als leicht negatives Stimmungsindikator wahrgenommen werden können.

false 0001503290 0001503290 2025-08-01 2025-08-01 0001503290 ACP:CommonSharesOfBeneficialInterestMember 2025-08-01 2025-08-01 0001503290 ACP:Sec5.250SeriesPerpetualPreferredSharesLiquidationPreference25.00Member 2025-08-01 2025-08-01 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported) August 1, 2025 (August 1, 2025)

  

abrdn Income Credit Strategies Fund

(Exact name of registrant as specified in its charter)

 

Delaware   811-22485   80-0660749

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

   

1900 Market Street, Suite 200

Philadelphia, PA

  19103
(Address of principal executive offices)   (Zip Code)

 

Registrants telephone number, including area code (800)-522-5465

 

(Former name or former address, if changed since last report.) 

  

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:  

 

Title of each class Trading Symbol(s) Name of each exchange on which
registered
Common Shares of Beneficial Interest ACP New York Stock Exchange
5.250% Series A Perpetual Preferred Shares (Liquidation Preference $25.00) ACP PRA New York Stock Exchange

  

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

¨ Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨   

 

 

 

 

 

 

Item 1.01. Entry into a Material Definitive Agreement.

 

On August 1, 2025, abrdn Income Credit Strategies Fund (NYSE: ACP) (the “Fund”) entered into a distribution agreement (the “Distribution Agreement”) with ALPS Distributors, Inc. (the “Distributor”), pursuant to which the Fund may offer and sell up to $75,000,000 of common shares of beneficial interest, par value $0.001 per share (“Common Shares”), from time to time through the Distributor, in transactions deemed to be “at the market” as defined in Rule 415 under the Securities Act of 1933, as amended (the “Offering”). Under the Investment Company Act of 1940, as amended, the Fund may not sell any Common Shares at a price below the current net asset value of such common shares, exclusive of any distributing commission or discount.

 

Pursuant to the Distribution Agreement, the Distributor may enter into sub-placement agent agreements with one or more selected dealers. The Distributor has entered into a sub-placement agent agreement, dated August 1, 2025 (the “Sub-Placement Agent Agreement”), with UBS Securities LLC (the “Sub-Placement Agent”) relating to the Common Shares to be offered under the Distribution Agreement.

 

The Offering is being made pursuant a prospectus supplement, dated August 1, 2025 and the accompanying prospectus, dated May 30, 2024, each of which constitute part of the Fund’s effective shelf registration statement on Form N-2 (File No. 333-277607) previously filed with the Securities and Exchange Commission (the “Registration Statement”).

 

The foregoing descriptions of the Distribution Agreement and the Sub-Placement Agent Agreement do not purport to be complete and are qualified in their entirety by reference to the full text of the Distribution Agreement filed with this report as Exhibit 1.1 and incorporated herein by reference, and the full text of the Sub-Placement Agent Agreement filed with this report as Exhibit 1.2 and incorporated herein by reference.

 

Item 8.01. Other Events

 

On August 1, 2025, the Fund commenced the Offering pursuant to the Fund’s Registration Statement. A copy of the opinion of Dechert LLP relating to the legality of the Common Shares is filed as Exhibit 5.1 to this report.

 

The Fund incorporates by reference the exhibits filed herewith into the Registration Statement.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

  

  1.1 Distribution Agreement between the Registrant and ALPS Distributors, Inc. 
     
  1.2 Sub-Placement Agent Agreement between ALPS Distributors, Inc. and UBS Securities LLC 
     
  5.1 Opinion of Dechert LLP 
     
  23.1 Consent of Dechert LLP (included in Exhibit 5.1) 
     
  104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  abrdn Income Credit Strategies Fund
     
Date: August 1, 2025 By: /s/ Robert Hepp
  Name: Robert Hepp
  Title: Vice President

 

 

 

FAQ

How many TEVA shares are being sold under this Form 144?

The insider intends to sell 52,742 ordinary shares.

What is the estimated market value of the proposed TEVA share sale?

The aggregate market value is approximately $799,437.

What percentage of TEVA’s outstanding shares does the sale represent?

Roughly 0.005 % of the 1.15 billion shares outstanding.

When were the shares originally acquired by the insider?

The shares were acquired on 01-Aug-2022 via a restricted share-unit award.

Which broker will handle the TEVA share sale and on which exchange?

The sale is to be executed through Citigroup Global Markets on the NYSE.
abrdn Income Credit Strategies Fund

NYSE:ACP

ACP Rankings

ACP Latest News

ACP Latest SEC Filings

ACP Stock Data

746.55M
125.47M
28.97%
0.09%
Asset Management
Financial Services
United Kingdom
Edinburgh